The coronavirus vaccine, developed by researchers at Oxford University, could soon enter human trials phase in India, the CEO of Serum Institute of India informed on Monday.
SII was chosen as a partner by the illustrious institute and its aide AstraZeneca, to mass-produce the COVID-19 vaccine when it is ready.
Yesterday, Oxford confirmed that the vaccine is safe and effective.
Here are more details.
The shot was able to generate neutralizing antibodies against SARS-CoV-2 in most of the participants. Besides, it also generated sufficient levels of virus-attacking T-cells, offering additional protection.
These cells were generated within 14 days of vaccination while the antibody response was triggered within 28 days.
UK-based AstraZeneca chose nine companies as partners, including SII
AstraZeneca, a biopharmaceutical giant based in the UK, has joined hands with nine companies to achieve its target of producing 2 billion doses.
One of the partners is SII, the largest vaccine manufacturer in the world. Its CEO Adar Poonawalla said he was extremely happy with the results.
He added that the company will soon apply for requisite permission for human trials in India.
After promising results, SII is focusing on the next stage
“We will be applying for the licensure trials to the Indian regulator in a week’s time. As soon as they grant us permission, we will begin with the trials for the vaccine in India. In addition, we will soon start manufacturing the vaccine,” Poonawalla added.
Firm is targeting August 2020 for human trials
In a conversation with HT, Poonawalla said the company was aiming to start human trials in India by August 2020.
He also revealed that his firm partnered with Oxford to produce the vaccine for India and middle, low-income countries.
Earlier, Poonawalla had said SII was aiming to produce the vaccine by year-end. A safe and effective product was the company’s goal, he had underlined…Read more>>